MIRATI THERAPEUTICS INC (MRTX) Stock Price, Quote, News and Overview
NASDAQ:MRTX - Nasdaq - US60468T1051 - Common Stock - Currency: USD
MRTX Quote, Performance and Key Statistics
58.7
-0.1 (-0.17%)
The current stock price of MRTX is 58.7 USD. In the past month the price decreased by -0.44%. In the past year, price increased by 10.57%.
MRTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.17 | 378.30B | ||
| AMGN | AMGEN INC | 16.39 | 174.51B | ||
| GILD | GILEAD SCIENCES INC | 25.47 | 146.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1683.76 | 125.39B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.5 | 77.34B | ||
| ARGX | ARGENX SE - ADR | 231.21 | 36.10B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.66B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.47B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
| BIIB | BIOGEN INC | 9.13 | 22.01B | ||
| NTRA | NATERA INC | N/A | 19.02B | ||
| GMAB | GENMAB A/S -SP ADR | 24.89 | 15.34B |
Related stock screener links
About MRTX
Company Profile
Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. The company is headquartered in San Diego, California and currently employs 587 full-time employees. The company went IPO on 2013-07-12. The firm is developing novel therapeutics to address the genetic and immunological promoters of cancer. The firm's product KRAZATI is an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Its MRTX1133 is an investigational, selective, and potent KRAS G12D inhibitor. Its MRTX1719 is an investigational synthetic lethal PRMT5 inhibitor designed to specifically target the PRMT5/ methylthioadensoine (MTA) complex. Its MRTX0902 is a potent, selective SOS1 inhibitor, designed to improve anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors. Its Sitravatinib is an investigational spectrum-selective kinase inhibitor designed to potently inhibit receptor tyrosine kinases (RTKs) and enhance immune responses through the inhibition of immunosuppressive signaling.
Company Info
MIRATI THERAPEUTICS INC
3545 Cray Court
San Diego CALIFORNIA 92121 US
CEO: Charles M. Baum
Employees: 587
Company Website: https://www.mirati.com/
Phone: 18583323410
MIRATI THERAPEUTICS INC / MRTX FAQ
What is the stock price of MIRATI THERAPEUTICS INC today?
The current stock price of MRTX is 58.7 USD. The price decreased by -0.17% in the last trading session.
What is the ticker symbol for MIRATI THERAPEUTICS INC stock?
The exchange symbol of MIRATI THERAPEUTICS INC is MRTX and it is listed on the Nasdaq exchange.
On which exchange is MRTX stock listed?
MRTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MIRATI THERAPEUTICS INC stock?
22 analysts have analysed MRTX and the average price target is 62.42 USD. This implies a price increase of 6.34% is expected in the next year compared to the current price of 58.7. Check the MIRATI THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MIRATI THERAPEUTICS INC worth?
MIRATI THERAPEUTICS INC (MRTX) has a market capitalization of 4.12B USD. This makes MRTX a Mid Cap stock.
How many employees does MIRATI THERAPEUTICS INC have?
MIRATI THERAPEUTICS INC (MRTX) currently has 587 employees.
What are the support and resistance levels for MIRATI THERAPEUTICS INC (MRTX) stock?
MIRATI THERAPEUTICS INC (MRTX) has a support level at 58.69 and a resistance level at 58.94. Check the full technical report for a detailed analysis of MRTX support and resistance levels.
Is MIRATI THERAPEUTICS INC (MRTX) expected to grow?
The Revenue of MIRATI THERAPEUTICS INC (MRTX) is expected to grow by 406.04% in the next year. Check the estimates tab for more information on the MRTX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy MIRATI THERAPEUTICS INC (MRTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MRTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MRTX, evaluating the profitability, health, valuation and growth aspects
- MIRATI THERAPEUTICS INC (MRTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MIRATI THERAPEUTICS INC (MRTX) Sales and EPS estimates to see what analysts future expectations are.
- MIRATI THERAPEUTICS INC (MRTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MIRATI THERAPEUTICS INC (MRTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- MIRATI THERAPEUTICS INC (MRTX) Stock Chart to make your own analysis
- MIRATI THERAPEUTICS INC (MRTX) Latest news and press-releases to stay up to date.
Does MIRATI THERAPEUTICS INC (MRTX) stock pay dividends?
MRTX does not pay a dividend.
When does MIRATI THERAPEUTICS INC (MRTX) report earnings?
MIRATI THERAPEUTICS INC (MRTX) will report earnings on 2024-02-26, after the market close.
What is the Price/Earnings (PE) ratio of MIRATI THERAPEUTICS INC (MRTX)?
MIRATI THERAPEUTICS INC (MRTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-12.22).
MRTX Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to MRTX. When comparing the yearly performance of all stocks, MRTX turns out to be only a medium performer in the overall market: it outperformed 69.11% of all stocks.
MRTX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to MRTX. No worries on liquidiy or solvency for MRTX as it has an excellent financial health rating, but there are worries on the profitability.
MRTX Financial Highlights
Over the last trailing twelve months MRTX reported a non-GAAP Earnings per Share(EPS) of -12.22. The EPS increased by 8.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -64.25% | ||
| ROE | -76.69% | ||
| Debt/Equity | 0 |
MRTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 69% to MRTX. The Buy consensus is the average rating of analysts ratings from 22 analysts.
For the next year, analysts expect an EPS growth of 14.07% and a revenue growth 406.04% for MRTX